DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
Status:
RECRUITING
Trial end date:
2027-12-30
Target enrollment:
Participant gender:
Summary
The purpose of this research study is determining the highest dose of the study drug DT2216 in combination with paclitaxel that can be safely and tolerably administered in recurrent ovarian cancer.
The names of the study drugs involved in this study are:
* DT2216 (a type of proteolysis-targeting chimera degrader of BCL-XL protein)
* Paclitaxel (a type of antimicrotubule agent)
Phase:
PHASE1
Details
Lead Sponsor:
Elizabeth Stover, MD, PhD
Collaborators:
American Society of Clinical Oncology Dialectic Therapeutics, Inc United States Department of Defense